Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Por Lukas Kirzinger, Sandra Boy, Jörg Marienhagen, Gerhard Schuierer, Reiner Neu, Michael Ried, Hans-Stefan Hofmann, Karsten Wiebe, Philipp Ströbel, Christoph May, Julia Kleylein-Sohn, Claudia Baierlein, Ulrich Bogdahn, Alexander Marx, Berthold Schalke
Publicado em 2016-01-01